

# OrbiMed Asia II Mauritius Limited

Fifth Floor, Ebene Esplanade, 24 Bank Street, Cybercity,  
Ebene, Mauritius  
Tel: (230) 401 2300 | Fax: (230) 401 2301

---

## Annexure B In-principle Confirmation

### Suraksha Diagnostic Private Limited ("Suraksha")

12/1, Premises No. 02-0327  
DG Block, Action Area 1D  
New Town, Kolkata - 700156  
E-mail: [cs@surakshanet.com](mailto:cs@surakshanet.com)

Dear Sir,

### Re: Proposed initial public offering of equity shares by Suraksha Diagnostic Private Limited (the "Offer")

We, OrbiMed Asia II Mauritius Limited (the "Company"), refer to your letter dated 7 May 2024 (the "Letter") in relation to the Offer. We would like to inform you that the Company is interested in participating in the Offer for Sale. We hereby acknowledge and accept all terms and conditions set out in the Letter. Kindly send us the detailed set of instructions and documents as indicated in your Letter so that we can take appropriate steps to participate in the Offer for Sale. Please see the relevant details below:

Name: OrbiMed Asia II Mauritius Limited  
Address: Fifth Floor, Ebene Esplanade, 24 Bank Street, Cybercity, Ebene – 72201, Mauritius  
E-mail ID: orbimed@internationalproximity.com  
Telephone: (230) 401 2300  
DP ID: IN300054  
Client ID: 10128942  
PAN No.: AABCO9986H

The Company will sell at OFS such number of shares which is equivalent to at least 20% of the fully diluted share capital of Suraksha. The Company currently holds 34.88% on a fully diluted basis.

Capitalised terms not specifically defined in this letter shall have the same meanings ascribed to such terms in the Letter. This In-Principle Confirmation may be shared by the addressee with, and relied upon, by any representatives and professional advisors of the addressee. This letter is for information and for inclusion (in part or full) in the draft red herring prospectus ("DRHP"), the red herring prospectus ("RHP") and the prospectus ("Prospectus") filed in relation to the Offer (collectively, the "Offer Documents") or any other Offer-related material, and may be shared by the Company with, and relied upon, by any representatives and professional advisors of the Company, the book running lead managers to the Offer ("Book Running Lead Managers") and their representatives, affiliates and professional and legal advisors, as well as any regulatory or statutory authority as required under applicable law.

We hereby consent to this letter being disclosed by the Book Running Lead Managers, if required (i) by reason of any law, regulation or order of a court or by any governmental or competent regulatory authority, or (ii) in seeking to establish a defence in connection with, or to avoid, any actual, potential or threatened legal, arbitral or regulatory proceedings or investigation. We hereby consent to the


# OrbiMed Asia II Mauritius Limited

Fifth Floor, Ebene Esplanade, 24 Bank Street, Cybercity,  
Ebene, Mauritius  
Tel: (230) 401 2300 | Fax: (230) 401 2301

---

submission of this letter as may be necessary, to the Securities and Exchange Board of India, the Registrar of Companies, West Bengal at Kolkata, the stock exchanges where the Equity Shares are proposed to be listed and any other regulatory or judicial authorities and/or for the records to be maintained by the Book Running Lead Managers in connection with the Offer and in accordance with applicable law.

Yours faithfully,



Harish Sumsurooah  
Director

Date: 13 May 2024